Table 1 Demographic and baseline characteristics (n = 27)
Gout patients (MSU-positive) (n = 23) | Non-gout patients (MSU-negative) (n = 4) | ||
|---|---|---|---|
Age, years, mean (SD), [range] | 62.6 (12.8) [39–85] | 63.5 (7.3) [55–71] | |
Male sex, no. (%) | 22 (96%) | 3 (75%) | |
Calcium pyrophosphate-positive (joint puncture) patients, no. (%) | 2 (9%) | 3 (75%) | |
Fulfilment of the ACR/EULAR 2015 gout classification criteria at the time of inclusion or 1 year after inclusion*, no. (%) | 23/23 (100%) | 0/4 (0%) | |
Self-reported disease duration, months, median (IQR), [range] | 108 (36; 180) [3–456] | 84 (39; 138) [6–180] | |
No. of joint attacks within 12 weeks, median (IQR), [range] | 1 (1; 4) [0–12] | 2 (1; 4) [0–4] | |
Self-reported region of pain/joint attacks (ever) (pct.): | |||
Fore- and midfoot | 22 (96%) | 4 (100%) | |
Ankle region (incl. Achilles tendon) | 8 (35%) | 1 (25%) | |
Knee | 16 (70%) | 1 (25%) | |
Finger and/or wrist | 11 (48%) | 4 (100%) | |
Visual analogue scale, pain, 0–100, median (IQR), [range] | 35 (10; 60) [5–90] | 38 (25; 60) [20–75] | |
No. of tender joints (0–60), median (IQR), [range] | 5 (2; 10), [0–26] | 7 (3; 11), [2–11] | |
No. of swollen joints (0–60), median (IQR), [range] | 1 (0; 5), [0–10] | 2 (1; 3), [0–3] | |
P-urate | (mmol/L), mean (SD), [range] | 0.50 (0.11) [0.32–0.70] | 0.40 (0.08) [0.32–0.50] |
(mg/dL), mean (SD), [range] | 8.4 (1.8) [5.4–11.8] | 6.7 (1.3) [5.4–8.4] | |
Number of patients with colour-coded DECT lesions (%) | 21/23 (91%) | 1/4 (25%) | |
Colour-coded DECT lesions (n) | 3918 | 115 | |
Colour-coded DECT lesions pr. patient, median (IQR), [range] | 47 (10; 226), [3–1308] | – | |